# Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

> **NCT00152425** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 392 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Certolizumab Pegol (CDP870)

## Key facts

- **NCT ID:** NCT00152425
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 392 (—)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152425, "Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00152425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*